
---
title: '阿诺、先声自研，百济引进，TNFR2能否成为肿瘤免疫下一张_王牌_？_专家点评'
categories: 
 - 新媒体
 - MIT 科技评论
 - 首页
headimg: 'https://p3-tt.byteimg.com/origin/pgc-image/1f1a9a7b0016481c8fc853932ff9b5d9?from=pc'
author: MIT 科技评论
comments: false
date: Fri, 07 May 2021 04:10:22 GMT
thumbnail: 'https://p3-tt.byteimg.com/origin/pgc-image/1f1a9a7b0016481c8fc853932ff9b5d9?from=pc'
---

<div>   
<p style="line-height: 30px;"><span style="font-size: 18px;">﻿</span><span style="color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">继 PD-1、CD47、TIGIT 靶点之后，肿瘤免疫疗法家族再添新成员 —— 肿瘤坏死因子受体 2（TNFR2）。</span></p><p data-track="2" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="3" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">TNFR2 是肿瘤坏死因子受体超家族 (tumor necrosis factor receptor superfamily, TNFRSF) 的成员之一，主要在肿瘤微环境中的调节性 T 细胞（Regulatory T Cells, 以下简称 “Tregs”）和肿瘤细胞表面高表达。</p><p data-track="4" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="5" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">众所周知，Tregs 通过免疫抑制性反应在维持机体免疫稳态中扮演着重要角色，调节 Tregs 的功能是一种经证实的有效癌症治疗策略。第一代免疫检测点抑制剂 Ipilimumab 的重要机制之一就是通过减少 Tregs 的数量来达到治疗肿瘤的目的。然而 Ipilimumab 抗体往往会将正常组织、血液中的 Tregs 一网打尽，从而引发全身毒性或者严重的自身免疫反应。</p><p data-track="6" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="7" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">因此，在不影响整个免疫系统稳态的前提下，如何特异性调节 Tregs 是肿瘤治疗的关键。</p><p data-track="8" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="9" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">“TNFR2 靶点的不同之处在于能够特异性清除肿瘤内部的 Tregs。TNFR2 在肿瘤微环境的 Tregs 中高表达，尤其在具有高抑制活性的 Tregs 中才会表达，其表达出来的组织特异性或肿瘤特异性，在肿瘤微环境层面表现出巨大的药用潜力，从而为肿瘤治疗提供了一种新策略。” 阿诺医药全球研发负责人何南海博士说。</p><p data-track="10" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="11" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">在刚刚结束的美国癌症协会 AACR 虚拟会议上，涵盖阿诺医药等多家制药公司的在研 TNFR2 管线相继亮相。目前，全球最快的 TNFR2 在研管线已经进入临床 I 期研究阶段。</p><p data-track="12" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="13" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">TNFR2 能否成为肿瘤免疫治疗的下一张 “王牌”？目前全球研发现状又如何？</p><p data-track="14" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><h1 class="pgc-h-arrow-right" data-track="15" style="font-size: 1.5em; margin-bottom: 20px; padding: 0px; font-weight: 700; border: 0px; line-height: 1.33333; color: rgb(34, 34, 34); position: relative; font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; text-align: justify;"><span style="font-size: 24px;">单药效果比肩“PD-1”，联合用药效果更佳</span></h1><p data-track="16" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal; text-align: center;"><br></p><p data-track="17" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">TNFR2 是肿瘤坏死因子（TNF）的受体之一，与受体 TNF 结合后，通过激活典型和非典型的 NF-kB 通路来控制细胞的生存和增殖。</p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: justify;"><img src="https://p3-tt.byteimg.com/origin/pgc-image/1f1a9a7b0016481c8fc853932ff9b5d9?from=pc" img_width="811" img_height="615" alt="阿诺、先声自研，百济引进，TNFR2欲成为肿瘤免疫下一张「王牌」" inline="0" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; cursor: zoom-in; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px;"></p></div><p data-track="19" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal; text-align: center;">图 TNFR2 分子信号通路（来源：Frontier）</p><p data-track="20" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="21" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">与 TNFR1 不同，TNFR2 仅在机体淋巴系统的少数亚群表达，如强抑制性 Tregs、髓源抑制性细胞（MDSCs）、内皮细胞和生长过程中的选择性神经元中，尤其在肿瘤微环境中高表达。同时还在多种肿瘤细胞表面大量表达，包括卵巢癌、结直肠癌等，具有促进肿瘤细胞增殖的功能。</p><p data-track="22" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="23" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">大量研究显示，TNFR2 抑制剂能够特异性抑制在肿瘤微环境中高表达 TNFR2 的 Tregs 的增殖和功能，同时特异性杀伤肿瘤细胞，用于抗肿瘤治疗；而 TNFR2 激活剂则可以激活 Tregs 细胞，抑制效应性 T 细胞（Effector T Cells，以下简称 “Teff”），进而下调免疫反应，可以用于自身免疫疾病治疗。</p><p data-track="24" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="25" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">具体而言，在自身免疫微环境中，自身反应性 CD8+Teff 比免疫抑制性 CD4+Tregs 更丰富，导致组织破坏。而 TNFR2 激动剂通过上调 Tregs 和选择性消除自身反应性 Teffs 来恢复免疫平衡；在肿瘤微环境中，肿瘤细胞被 Tregs 浸润，抑制 Teff，促进肿瘤生长。而 TNFR2 通过清除 Tregs 和激活 Teff 来恢复免疫平衡，杀伤肿瘤细胞。</p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: justify;"><img src="https://p1-tt.byteimg.com/origin/pgc-image/de4babf03f554ddaa8245cdae1099ea2?from=pc" img_width="1162" img_height="1172" alt="阿诺、先声自研，百济引进，TNFR2欲成为肿瘤免疫下一张「王牌」" inline="0" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; cursor: zoom-in; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px;"></p></div><p data-track="27" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal; text-align: center;">图 | 自身免疫和肿瘤微环境中 TNFR2 激活和抑制作用（来源：Trends in Molecular Medicine）</p><p data-track="28" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="29" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">有研究报道指出，TNFR2 已经成为免疫逃逸、肿瘤生长以及检查点阻断抵抗性的潜在诱因。TNFR2 抑制剂抗体能够抑制人卵巢癌细胞和肿瘤相关 Tregs 的增殖。</p><p data-track="30" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="31" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">表达 CTLA-4 或 PD-1 的 Tregs 亚群在免疫调节中发挥着关键作用，但是利用 CTLA-4 或 PD-1 抗体调节 Tregs 时，会导致免疫失调甚至严重的自身免疫疾病等副作用。同时通过调节 Tregs 发挥作用的 TNFR2 是否也会面临毒副作用限制？</p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: justify;"><img src="https://p6-tt.byteimg.com/origin/pgc-image/47ed9cd3f9a4400dac635d21150f8265?from=pc" img_width="770" img_height="675" alt="阿诺、先声自研，百济引进，TNFR2欲成为肿瘤免疫下一张「王牌」" inline="0" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; cursor: zoom-in; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px;"></p></div><p data-track="33" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal; text-align: center;">图 | 调节性 T 细胞上表达的免疫调节受体（来源：Cell）</p><p data-track="34" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="35" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">多项研究表明，TNFR2 可能对肿瘤微环境具有特异识别性，甚至比其他免疫疗法更能针对性地治疗肿瘤，安全性更强。</p><p data-track="36" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="37" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">事实上，这种选择性与 TNFR2 的分布和表达密切相关。TNFR2 在其他细胞类型中的表达受限，为其成为一种更具选择性的疗法提供了理论依据。</p><p data-track="38" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="39" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">研究人员发现缺乏 TNFR2 基因的小鼠表现出了更好的抗肿瘤免疫应答反应，而且没有引发全身自身免疫反应。进一步发现 TNFR2 的缺失只影响了在肿瘤微环境中高表达的 Tregs 群体，而其他组织中的 Tregs 仍然正常工作，维持免疫系统平衡。</p><p data-track="40" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="41" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">“Treg 相关的抗肿瘤治疗策略关键在于是否能够有效且精准地调节 Tregs，而 TNFR2 能够选择性调节 Tregs，与其他免疫检查点抑制剂相比更具有特异性。” 何南海说。</p><p data-track="42" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="43" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">“肿瘤免疫检查点治疗虽然取得了突破性进展，但是依靠联合用药提高治疗效果已经成为一种开发趋势。TNFR2 作为特异性调节肿瘤微环境的靶点，其在联合用药的潜力也将逐渐被挖掘。阿诺医药在研 TNFR2 靶点的开发策略也是联合用药，预计在联合用药中更能够特异性激活抗肿瘤活性，从而更大程度地发挥药效。” 何南海表示。</p><p data-track="44" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="45" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">何南海在生辉的采访中表示，阿诺医药在研 TNFR2 抑制剂在动物模型单独给药试验中显示出了良好的抗肿瘤活性，结合 PD- (L) 1 效果更为显著。</p><p data-track="46" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="47" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">“作为调节免疫的一种强有力手段，Treg 靶点具有很大的潜力，未来 TNFR2 的研究也将逐渐成为热门赛道。TNFR2与其他靶点联合用药的治疗效果在未来完全有潜力比肩‘PD-(L)1’ 所带来的惊喜。”</p><p data-track="48" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><h1 class="pgc-h-arrow-right" data-track="15" style="font-size: 1.5em; margin-bottom: 20px; padding: 0px; font-weight: 700; border: 0px; line-height: 1.33333; color: rgb(34, 34, 34); position: relative; font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; text-align: justify;"><span style="font-size: 24px;">开始产业化，潜力巨大</span></h1><p data-track="50" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="51" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">与 PD-1、LAG-3、4-1BB 相比，近年来 TNFR2 的基础研究并不算火热。在 Google Scholar 上搜索 TNFR2 关键词，从 2017 年到 2021 年间共发表了 8330 篇学术论文，而 PD-1 共有 63700 篇，LAG-3 有 16400 篇，4-1BB 有 10300 篇学术论文。</p><p data-track="52" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="53" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">“现代肿瘤免疫治疗始于 2011 年，目前对于肿瘤免疫治疗的整体认识还处于起步阶段。自免疫检测点抑制剂问世以来，无论是学界还是产业界一开始都只在探寻与 CTLA-4/PD-(L) 1 机制相似的靶点。而TNFR2在老鼠中的基因敲除试验显示，它的缺失对于稳态免疫系统的影响甚小，所以其潜力一度被忽视。” 何南海补充道。</p><p data-track="54" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="55" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">不过，随着对于新靶点的不断深入挖掘，TNFR2 的重要性日渐受到关注。根据 Clinicaltrials.gov 数据查询，全球共有 40 项针对 TNFR2 靶点的临床试验正在进行中。</p><p data-track="56" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="57" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">可以说，TNFR2 正在成为肿瘤免疫治疗的潜在新靶点，其抑制剂的开发更是成为当前抗癌新药研究的热点。</p><p data-track="58" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="59" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">“从 TNFR2 的全球研发进展来看，入局者已经不在少数，不过整体进展相差不大，绝大多数公司还处于早期临床前阶段，最快的研发进展推进到了临床 I 期阶段。” 何南海这样分析国内外研发现状。</p><p data-track="60" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="61" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">根据目前已披露的资料，国内外生物制药公司已经相继入局。国内包括百济神州、阿诺医药、先声药业等，国外包括 Boston Immune Technologies and Therapeutics（BITT）、BioInvent、HiFiBiO Therapeutics、Apexigen、Amgen 等。</p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: justify;"><img src="https://p3-tt.byteimg.com/origin/pgc-image/488f9cbabb454c568678dfeb52948139?from=pc" img_width="1080" img_height="386" alt="阿诺、先声自研，百济引进，TNFR2欲成为肿瘤免疫下一张「王牌」" inline="0" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; cursor: zoom-in; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px;"></p></div><p data-track="64" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">2021 年 2 月，百济神州超 1 亿美元引进 BITT 在研 TNFR2 抑制剂抗体 BITE2101，双方将共同推进临床 I 期试验，包括推进 TNFR2 与 PD-1 抗体替雷利珠单抗的联合用药管线；先声药业在 AACR 会议上连发三篇摘要，公布了在研 TNFR2 管线的体内、体外试验数据；阿诺医药也在 AACR 会议上公布了 TNFR2 在研管线最新进展，数据显示，AN3025 抗体活性很好，可以阻断 TNFR2 与其配体结合，并单药抑制了 MC38 肿瘤生长。</p><p data-track="65" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;"><br></p><p data-track="66" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal;">“TNFR2 的整体研发其实也是机遇和挑战并存。一方面，TNFR2 研发赛道才刚刚开始，跑出来的机会很多；另一方面，开发速度、临床开发策略及适应症的选择等方面同样面临着严峻的考验。” 何南海总结道。</p>  
</div>
            